About Dr David Woodhouse
David Woodhouse has had extensive experience in various aspects of health care. These roles have included clinical obstetrics and gynaecology, Medical Directorships in the pharmaceutical industry, as well as administrative and leadership roles within the hospital system and the RANZCOG.
He originally trained as a specialist Obstetrician and Gynaecologist in Australia and the UK, practising at the Crown Street Women’s Hospital and the Caroline Chisholm Unit at Liverpool in South West Sydney. He holds fellowships of both the Royal and the Royal Australian and New Zealand Colleges of Obstetricians and Gynaecologists as well as a Masters in Reproductive Medicine, a Masters in Bioethics and a Fellowship of the Australian Institute of Company Directors. At Crown Street he held the position of Clinical Supervisor and assisted in the establishing of its fetal laboratory and natural birthing centre.
He has served in several executive positions on the State and Federal Councils of the RANZCOG being
ultimately Chairman of the NSW State Committee and Senior Vice President of the College. During this time, he conducted the review of Obstetric Services in the Murray District for the NSW Health Department and served as Chairman of the NHMRC Working Party on the use of Anti D gamma globulin in Obstetrics.
He was recruited into the pharmaceutical industry in 1989 as Medical Director for Upjohn to introduce the prostaglandins into Australia. This was followed by Medical Directorships of Upjohn, Pharmacia & Upjohn, Pharmacia, Serono (Australia and Japan) and Organon Australia.
Dr Woodhouse has developed and extended professional relationships with Key Opinion Leaders over a wide range of therapeutic areas though particularly in Gynaecology, menopausal medicine and Assisted
Reproductive Technologies (ART). He founded the Menopause Clinic at the Caroline Chisholm Hospital in Sydney and was responsible for the pivotal study on the safety and efficacy of Continuous Combined HRT conducted by Upjohn.
He was closely involved in all aspects of ART including commercial development of the product ranges of both Serono and Organon in Australia, professional education within IVF clinics and the development of clinical trials for fertility research.
In Japan he assisted with the establishing and accreditation review of the 13 Centres of Excellence known as JISART and prepared the market for the introduction of recombinant FSH. At Organon he was closely involved with the marketing and product defence of the novel contraceptive agents Implanon and NuvaRing as well as speaking extensively on Livial. During this period, he developed training programs and support materials for the use of antagonist protocols in IVF/ICSI.
Since October 2009 he has been senior consulting doctor with the Australian Menopause Centre.